Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology and Surgical segments. It researches and develops therapeutic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels. In addition, the company offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and mouth wash Granules; and collagen-based artificial dermis. It has license agreements with Mitotech S.A. and Mitotech LLC for clinical trial of ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration. The company was founded in 1990 and is headquartered in Zhuhai, China.